WO2002017899A3 - Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration - Google Patents

Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration Download PDF

Info

Publication number
WO2002017899A3
WO2002017899A3 PCT/US2001/027064 US0127064W WO0217899A3 WO 2002017899 A3 WO2002017899 A3 WO 2002017899A3 US 0127064 W US0127064 W US 0127064W WO 0217899 A3 WO0217899 A3 WO 0217899A3
Authority
WO
WIPO (PCT)
Prior art keywords
signal transduction
edg
sphingosine
regulation
receptor mediated
Prior art date
Application number
PCT/US2001/027064
Other languages
French (fr)
Other versions
WO2002017899A2 (en
Inventor
Timothy Hla
Meng-Jer Lee
Kevin P Claffey
Nicolas Ancellin
Shobha Thangada
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Priority to AU2001288563A priority Critical patent/AU2001288563A1/en
Publication of WO2002017899A2 publication Critical patent/WO2002017899A2/en
Publication of WO2002017899A3 publication Critical patent/WO2002017899A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for the inhibition of angiogenesis are presented, comprising affecting the response of the EDG-1 receptor by the administration of pharmaceutically effective antagonists of EDG-1 signal transduction. This invention is based in part on the discovery that Akt protein kinase phosphorylation is required for endothelial cell chemotaxis mediated by the EDG-1 G protein-coupled receptor. This invention relates to the use of modifiers of EDG-1 signal transduction to treat disorders of undesired angiogenesis.
PCT/US2001/027064 2000-08-31 2001-08-31 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration WO2002017899A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001288563A AU2001288563A1 (en) 2000-08-31 2001-08-31 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65184600A 2000-08-31 2000-08-31
US09/651,846 2000-08-31

Publications (2)

Publication Number Publication Date
WO2002017899A2 WO2002017899A2 (en) 2002-03-07
WO2002017899A3 true WO2002017899A3 (en) 2004-03-25

Family

ID=24614457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027064 WO2002017899A2 (en) 2000-08-31 2001-08-31 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration

Country Status (2)

Country Link
AU (1) AU2001288563A1 (en)
WO (1) WO2002017899A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484981A (en) * 2020-04-26 2020-08-04 四川省人民医院 Method for constructing retinal neovascular disease model and application

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533852A (en) * 2002-07-18 2005-11-10 セレテック エルエルシー Method for treating symptoms associated with Edg-1 receptor
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
SI1812797T1 (en) * 2004-10-28 2013-06-28 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9217749B2 (en) 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
AU2015242791B2 (en) * 2014-04-04 2017-08-17 Osaka University Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035259A1 (en) * 1997-12-30 1999-07-15 Nps Allelix Corp. Identification of lysolipid receptors involved in inflammatory response
WO1999046277A1 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035259A1 (en) * 1997-12-30 1999-07-15 Nps Allelix Corp. Identification of lysolipid receptors involved in inflammatory response
WO1999046277A1 (en) * 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ENGLISH, DENIS ET AL: "Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis", JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH ( 1999 ), 8(6), 627-634, XP008018336 *
LEE, MENQ-JER ET AL: "Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate", CELL (CAMBRIDGE, MASSACHUSETTS) ( 1999 ), 99(3), 301-312, XP002244485 *
LEE, OK-HEE ET AL: "Sphingosine 1-Phosphate Induces Angiogenesis: Its Angiogenic Action and Signaling Mechanism in Human Umbilical Vein Endothelial Cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS ( 1999 ), 264(3), 743-750, XP002244342 *
NAKAJIMA N ET AL: "Expression and characterization of Edg-1 receptors in rat cardiomyocytes: calcium deregulation in response to sphingosine 1-phosphate.", EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS. GERMANY SEP 2000, vol. 267, no. 18, September 2000 (2000-09-01), pages 5679 - 5686, XP002250815, ISSN: 0014-2956 *
OKAMOTO, H. ET AL: "Sphingosine 1-Phosphate Stimulates Gi- and Rho-Mediated Vascular Endothelial Cell Spreading and Migration", THROMBOSIS RESEARCH ( 2000 ), 99(3), 259-265, XP002244344 *
WANG, FANG ET AL: "Sphingosine 1-phosphate stimulates cell migration through a Gi-coupled cell surface receptor. Potential involvement in angiogenesis", JOURNAL OF BIOLOGICAL CHEMISTRY ( 1999 ), 274(50), 35343-35350, XP002244343 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111484981A (en) * 2020-04-26 2020-08-04 四川省人民医院 Method for constructing retinal neovascular disease model and application
CN111484981B (en) * 2020-04-26 2021-02-02 四川省人民医院 Method for constructing retinal neovascular disease model and application

Also Published As

Publication number Publication date
AU2001288563A1 (en) 2002-03-13
WO2002017899A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
WO2005051942A8 (en) Indazole compounds and methods of use thereof as protein kinase inhibitors
EP1595871A3 (en) Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
WO2004014881A3 (en) '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
WO2002017899A3 (en) Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration
WO2002085925A3 (en) Melanocortin receptor ligands
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
WO1999026927A3 (en) Metabotropic glutamate receptor antagonists for treating central nervous system diseases
WO2003042172A3 (en) C-5 modified indazolylpyrrolotriazines
MXPA03007513A (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists.
WO2001023389A3 (en) Certain alkylene diamine-substituted heterocycles
EA200200560A1 (en) Polycycloalkylpurins as antagonists of adenosine receptors
PL351125A1 (en) Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
WO2006102308A3 (en) Beta-lactamyl vasopressin v1b antagonists
MXPA05005895A (en) Pharmaceutical composition of 1-(3, 4-dimethoxyphenyl) -4-methyl-5 -ethyl-7- methoxy-8 -hydroxy -5h-2, 3-benzodiazepine and uses thereof.
EP1588706A3 (en) Use of AT1 receptor antagonists or AT2 receptor modulator for the treatment of conditions or diseases associated with the increase of AT1 or AT2 receptors
WO2005030187A3 (en) Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
WO2001098279A3 (en) Bis-arylsulfones
WO2004087048A3 (en) Benzamide modulators of metabotropic glutamate receptors
WO2002018348A3 (en) Quinazoline derivatives as alpha-1 adrenergic antagonists
WO2001034604A3 (en) Adenosine receptor antagonists and methods of making and using the same
TW200509920A (en) Imidazole derivatives
NO20055758L (en) Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists
NO20060112L (en) Imidazole Derivatives III
WO2004111047A3 (en) Cycloalkanepyrrolopyridines as dp receptor antagonists
EP1280781A4 (en) 5-ht 7 receptor antagonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP